Newsbenzinga
ARS Pharma Lowers 2026 Cash Operating Expense Guidance To $248M And Reaffirms Path To Cash-Flow Breakeven In 2027
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Comments —
Loading comments…